-
Signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
-
Issuer symbol
-
VRTX
-
Transactions as of
-
03 Dec 2025
-
Net transactions value
-
-$23,131,913
-
Form type
-
4
-
Filing time
-
05 Dec 2025, 16:10:39 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| LEIDEN JEFFREY M |
Executive Chairman, Director |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON |
/s/ Christiana Stevenson, Attorney-in-Fact |
05 Dec 2025 |
0001242825 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VRTX |
Common Stock |
Options Exercise |
$5,518,332 |
+63,781 |
+265% |
$86.52 |
87,807 |
03 Dec 2025 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Sale |
$1,968,148 |
-4,469 |
-5.1% |
$440.40 |
83,338 |
03 Dec 2025 |
Direct |
F1, F2, F3 |
| transaction |
VRTX |
Common Stock |
Sale |
$582,463 |
-1,320 |
-1.6% |
$441.26 |
82,018 |
03 Dec 2025 |
Direct |
F1, F2, F4 |
| transaction |
VRTX |
Common Stock |
Sale |
$1,094,285 |
-2,469 |
-3% |
$443.21 |
79,549 |
03 Dec 2025 |
Direct |
F1, F2, F5 |
| transaction |
VRTX |
Common Stock |
Sale |
$1,933,855 |
-4,352 |
-5.5% |
$444.36 |
75,197 |
03 Dec 2025 |
Direct |
F1, F2, F6 |
| transaction |
VRTX |
Common Stock |
Sale |
$3,519,478 |
-7,899 |
-11% |
$445.56 |
67,298 |
03 Dec 2025 |
Direct |
F1, F2, F7 |
| transaction |
VRTX |
Common Stock |
Sale |
$515,002 |
-1,152 |
-1.7% |
$447.05 |
66,146 |
03 Dec 2025 |
Direct |
F1, F2, F8 |
| transaction |
VRTX |
Common Stock |
Sale |
$1,041,170 |
-2,320 |
-3.5% |
$448.78 |
63,826 |
03 Dec 2025 |
Direct |
F1, F2, F9 |
| transaction |
VRTX |
Common Stock |
Sale |
$2,645,059 |
-5,880 |
-9.2% |
$449.84 |
57,946 |
03 Dec 2025 |
Direct |
F1, F2, F10 |
| transaction |
VRTX |
Common Stock |
Sale |
$2,621,021 |
-5,809 |
-10% |
$451.20 |
52,137 |
03 Dec 2025 |
Direct |
F1, F2, F11 |
| transaction |
VRTX |
Common Stock |
Sale |
$7,090,948 |
-15,681 |
-30% |
$452.20 |
36,456 |
03 Dec 2025 |
Direct |
F1, F2, F12 |
| transaction |
VRTX |
Common Stock |
Sale |
$4,696,602 |
-10,360 |
-28% |
$453.34 |
26,096 |
03 Dec 2025 |
Direct |
F1, F2, F13 |
| transaction |
VRTX |
Common Stock |
Sale |
$942,305 |
-2,070 |
-7.9% |
$455.22 |
24,026 |
03 Dec 2025 |
Direct |
F1, F2, F14 |
| transaction |
VRTX |
Common Stock |
Options Exercise |
$91.05 |
+1 |
+0% |
$91.05 |
24,027 |
04 Dec 2025 |
Direct |
|
| holding |
VRTX |
Common Stock |
|
|
|
|
|
440 |
03 Dec 2025 |
401(k) |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-63,781 |
-100% |
$0.000000 |
0 |
03 Dec 2025 |
Common Stock |
63,781 |
$86.52 |
Direct |
F15 |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-1 |
-100% |
$0.000000 |
0 |
04 Dec 2025 |
Common Stock |
1 |
$91.05 |
Direct |
F15 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: